Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy
Mahiques Santos, L.; Martínez Menchón, T.; Sánchez Carazo, Jé.Luis.; Fortea Baixauli, Jé.Miguel.
Medicina Clinica 125(4): 159
2005
ISSN/ISBN: 0025-7753 PMID: 15989862 Document Number: 589379
Document emailed within 1 workday
Related Documents
Kamili, Q.U.A.; Miner, A.; Hapa, A.; Menter, A. 2011: Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review Journal of Drugs in Dermatology: Jdd 10(5): 539-544Sri, J.C.; Tsai, C.L.; Deng, A.; Gaspari, A.A. 2007: Osteomyelitis occurring during infliximab treatment of severe psoriasis Journal of Drugs in Dermatology: Jdd 6(2): 207-210
Malaviya, R.; Sun, Y.; Tan, J.K.; Magliocco, M.; Gottlieb, A.B. 2006: Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis Journal of Drugs in Dermatology: Jdd 5(9): 890-893
Weinberg, J.M.; Saini, R.; Tutrone, W.D. 2002: Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept Journal of Drugs in Dermatology: Jdd 1(3): 303-310
Tutrone, W.D.; Saini, R.; Weinberg, J.M. 2004: Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept Idrugs: the Investigational Drugs Journal 7(1): 45-49
Pietrzak, A.; Chodorowska, G.; Jazienicka, I.; Junak-Bojarska, A.; Roliński, J. 2003: New development in the treatment of psoriasis--infliximab Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 58(1): 322-327
Bobbitt, S.A.; Klaus, E.M.; Stringer, E.; Chowdhury, D.; Finlayson, L. 2016: Treatment of refractory pyoderma gangrenosum with infliximab in a 17-month-old boy Dermatology Online Journal 22(4)
Weinberg, J.M.; Saini, R. 2003: Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept Cutis 71(1): 25-29
Bermejo, F.; López-Sanroman, A.; Hinojosa, J.; Castro, L.; Jurado, C.; Gómez-Beldal, A.B. 2004: Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 96(2): 94-101
Rathod, D.; Weinberg, J.M..; Yamauchi, P.S..; Kircik, L.H..; Wollina, U.; Lotti, T.; Goldust, M. 2019: Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report Journal of Drugs in Dermatology: Jdd 18(4): 394-396
Salvarani, C.; Cantini, F.; Niccoli, L.; Catanoso, M.Grazia.; Macchioni, P.; Pulsatelli, L.; Padula, A.; Olivieri, I.; Boiardi, L. 2003: Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study Journal of Rheumatology 30(4): 760-763
Cobo-Ibáñez, T.; Muñoz-Fernández, S.; Hidalgo-Barrero, V.; Martín-Mola, E. 2006: Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment Medicina Clinica 126(1): 34-35
Labarca, Cán.; Massardo, L.; García, P.I.; Jacobelli, S. 2003: Effectiveness of infliximab in patients with inflammatory arthritis refractory to conventional treatment Revista Medica de Chile 131(10): 1157-1164
Kalb, R.E.; Blauvelt, A.; Sofen, H.L.; Chevrier, M.; Amato, D.; Calabro, S.; Wang, J.; Schenkel, B.; Gottlieb, A.B. 2013: Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial Journal of Drugs in Dermatology: Jdd 12(8): 874-880
Skroza, N.; Proietti, I.; Bernardini, N.; La Viola, G.; Nicolucci, F.; Tolino, E.; Zuber, S.; Potenza, C. 2012: Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report Cutis 90(3): 120-122
Price, J.; Bhosle, M.; Feldman, S.R.; Balkrishnan, R. 2007: Outcomes associated with the use of biologic agents in moderate to severe psoriasis Journal of Drugs in Dermatology: Jdd 6(3): 259-267
Weinberg, J.M.; Bottino, C.J.; Lindholm, J.; Buchholz, R. 2005: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept Journal of Drugs in Dermatology: Jdd 4(5): 544-555
Famenini, S.; Wu, J.J. 2013: Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases Journal of Drugs in Dermatology: Jdd 12(8): 939-943
Pariser, D.M.; Green, L.J.; Stein Gold, L.; Sugarman, J.L.; Lin, T.; Pillai, R. 2018: Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy Journal of Drugs in Dermatology: Jdd 17(7): 723-726
Imaizumi, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Amano, K.; Hatano, S.; Kuwabara, K.; Sobajima, J.; Ishiguro, T.; Ohsawa, T.; Kumamoto, K.; Kumagai, Y.; Haga, N.; Ishida, H. 2012: Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 2185-2188